Fig. 6: Representative in vivo images of FAPI-800CW and FAPI-ALB-800CW uptake in mouse paws following a 1 nmol IV bolus. | npj Imaging

Fig. 6: Representative in vivo images of FAPI-800CW and FAPI-ALB-800CW uptake in mouse paws following a 1 nmol IV bolus.

From: Increased imaging ligand hydrophilicity and improved pharmacokinetic properties provides enhanced in vivo targeting of fibroblast activation protein

Fig. 6

Images are shown with identical thresholding. A In vivo image of FAPI-800CW in healthy paws. B Inflamed paws post dosing with FAPI-800CW at 5 h (top) and FAPI-ALB-800CW at 24 h (bottom). Here, the images represent the maximum NIR signal without competition. C Reduced 800CW signal observed in inflamed paws of CIA mice when blocked with FAPI-AF647 (top) or FAPI-ALB-AF647 (bottom). Blocking doses were co-administered with a 50-fold molar excess. Here, greater reductions in NIR signal represent improved targeting of the blocking agent.

Back to article page